The two kidneys filter blood, take out waste, and make urine. Most kidney diseases attack the nephrons of the kidney. This damage may leave kidneys unable to remove wastes. Causes can include genetic problems, injuries, or medicines.
Programs + Services
The Tufts MC Kidney and Blood Pressure Center provides both one-time consultations and ongoing care for chronic or acute kidney disease and high blood pressure.
More information about programs and services
Research + Clinical Trials
The purpose of this clinical trial is to see if the drug Finerenone is safe and effective in patients with in participants with non-diabetic chronic kidney disease. Additionally, while finerenone has been approved for other patient populations, this study will collect additional safety information about finerenone to determine how it affects the body.
More information about research and clinical trials
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More information about research and clinical trials
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
More information about research and clinical trials
This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.
More information about research and clinical trials
The purpose of this study is to assess the safety and efficacy of an investigational oral drug called difelikefalin, in reducing the intensity of itching and the impact of itch on your quality of life. The FDA already approved a intravenous(IV) form of the drug to treat moderate-to-severe itchiness in people undergoing hemodialysis. This study continues tests the oral form of the drug in reducing itchiness in people not on dialysis. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill.
More information about research and clinical trials
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More information about research and clinical trials
We are testing an investigational drug called RGLS8429. “Investigational” means that the study drug being tested is not approved by the United States Food and Drug Administration for use in humans. The main purpose of this study is to get more information about the safety, tolerability (whether side effects can be handled by a subject), pharmacodynamics (how it works on the kidneys), and pharmacokinetics (how the drug is processed in the body) of RGLS8429 in patients with ADPKD. This is a randomized, double blind study, meaning that subjects will be assigned either to the investigational drug or to a placebo. RGLS8429 will be administered by subcutaneous injection (a shot just under the skin) and is being tested in different dose levels.
More information about research and clinical trials
The purpose of this trial is to see if the drug ravulizumab is safe and effective in patients with thrombotic microangiopathy (TMA). This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug. You will recieve the drug or placebo for about 6 months and then have follow-up appoinments for about 6 months.
More information about research and clinical trials
The purpose of this clincial trial is to see if the drug CSL346 (developed by CSL Behring) is safe and effective in treating type II diabetic kidney disease. We will look at whether the drug decreases the amount of protein in your urine. The drug is given through the vein and under the skin by research nurses under the supervision of the research doctor. This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug.
More information about research and clinical trials
This study looks at whether the drug GFB-887 (developed by Goldfinch Bio) can slow the progression of kidney disease in patients with FSGS and treatment-resistant minimal change disease. The drug works similarly to drugs called calcineurin inhibitors (aka CNIs, such as tacrolimus or cyclosporine) but without some of the side effects those drugs can have. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill. Once you complete this study, you will have the option to enroll in an additional study where all participants receive the drug.
More information about research and clinical trials
Good communication among patients, their families and loved ones, and their medical care providers is important when figuring out how to treat chronic diseases like kidney disease. A lot of people may not know their choices for how to treat kidney disease, and this can lead to rushed decisions or even a sense that there weren't any choices to make. In this study, we are trying to find out if a decision-aid program on a computer can help people with kidney disease have more confidence in their decisions and have better agreement about their decisions with their families and loved ones.
More information about research and clinical trials
